Sarabjit Kaur Nangra

Healthcare major Sun Pharmaceutical Industries' Profit more than doubled to Rs 2,235.1 crore in the quarter ended September 2016 compared with Rs 1,028.8 crore in year-ago period, driven by overall healthy business performance.

Revenue miss: How will D-Street react to TCS' nos?

Sarabjit Kaur Nangra, VP-research from Angel Broking says while the revenue miss is disappointing, but the core matrix drivers in terms of volume has done fairly well. The miss has probably come from currency, she adds

Sun will turn Ranbaxy profitable; stock fall brief: Angel

Sarabjit Kaur Nangra of Angel Broking is neutral on Cipla as of now because the price has run up ahead of fundamentals.

Tech Mah Q3 nos in line; experts remain bullish on stock

Sarabjit Kaur Nangra, VP - Research, Angel Broking said the numbers were broadly in line with expectations. She remains bullish on the stock with a longer-term perspective though in the near-term she sees little upside.

Ranbaxy Q3 disappoints; US mkt, Diovan led to loss: Angel

Speaking to CNBC-TV18, Sarabjit Kaur Nangra of Angel Broking said on the bottomline, margins suffered due to forex loss. The drug maker reported a forex loss of Rs 132.6 crore versus gain of Rs 10.1 crore from a year ago period.

TCS Q3 nos on expected lines; mgmt guidance key: Experts

According to both Sandip Agarwal of Edelweiss Financial Services and Sarabjit Kaur Nangra, of Angel Broking TCS Q3 numbers were more or less in line with expectations.

Experts disappointed with Sun Pharma Q2 nos but not bearish

Sun Pharma for its second quarter ended September 2014 a net profit of Rs 1,362 crore during the same period of previous fiscal.

Buy IPCA; it is well valued for long-term investors: Angel

Sarabjit Kaur Nangra of Angel Broking says the stock is very well valued at the current prices and adds that the company‘s cautiousness about maintaining its profitability is a positive.

Dr Reddy's Q2: Revenue hit by high expenditure, says expert

Dr Reddy's Laboratories reported a fall of 16.8 percent in its second quarter consolidated net profit to Rs 574 crore against Rs 690.2 crore in the year-ago period.

Here's how experts read Ranbaxy's Q2FY15 earnings

Ranbaxy Laboratories has turned profitable in the second quarter of current financial year. The company reported consolidated net profit of Rs 478 crore during the quarter as against loss of Rs 454 crore in the year-ago period.

Here's what experts make of Lupin's Q2 earnings

Sarabjit Kaur Nangra of Angel Broking believes the company‘s current growth rate should not be difficult to maintain apart from big launches.

Here's how experts read Wipro's Q2FY15 earnings

In an interview to CNBC-TV18, Ravi Menon, AVP - IT, Centrum Broking, Vibhor Singhal, IT Analyst, Phillip Capital and Sarabjit Kaur Nangra, VP - Research Pharma, Angel Broking spoke about Wipro‘s financial performance in the quarter gone by and the road ahead.

CMC merger could trigger upgrade for TCS: Angel Broking

"We believe the TCS stock will react positively because a 6.4 percent quarter on quarter (QoQ) core dollar growth is definitely not a small by any chance," Sarabjit Kaur Nangra VP - Research Pharma, Angel Broking said.

Like Infosys on better margins, mgmt remarks: Angel Broking

According to Sarabjit Kaur Nangra, the improved EBIT margins and optimistic management commentary is a huge positive. However, attrition rate still remains a concern.

How experts are reading Dr Reddy's Laboratories Q3 results

Q3 earnings have been broadly in line with our expectation. We were expecting good traction in bot Russia and America as they have been key drivers for the company for a pretty long time, Sarabjit Kaur Nangra of Angel Broking said.

Healthy sales, operational growth push Ranbaxy 6% up: Angel

Ranbaxy Laboratories, which has been struggling for drug production due to USFDA issues, reported a net loss of Rs 159 crore for the fourth quarter (October-December) as against loss of Rs 486.55 crore in same quarter last year.

Ranbaxy disappoints on lower OPM, net profit: Angel Broking

Angel Broking's Sarabjit Kaur Nangra believes the Q2 earnings of Ranbaxy is lower than expectations as both the operating performance and the net profit of the company are disappointing